Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Letter by Lipshultz Regarding Article, "Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?"

Literature DB >> 29599279

Letter by Lipshultz Regarding Article, "Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?"

Steven E Lipshultz¹.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2018 PMID： 29599279 PMCID： PMC5997275 DOI： 10.1161/CIRCRESAHA.118.312918

Source DB: PubMed Journal: Circ Res ISSN： 0009-7330 Impact factor: 17.367

× No keyword cloud information.

14 in total

Review 1. The relevance of information generated by in vitro experimental models to clinical doxorubicin cardiotoxicity.

Authors: Steven E Lipshultz; Harvey Cohen; Steven D Colan; Eugene H Herman
Journal: Leuk Lymphoma Date: 2006-08

2. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association.

Authors: Steven E Lipshultz; M Jacob Adams; Steven D Colan; Louis S Constine; Eugene H Herman; Daphne T Hsu; Melissa M Hudson; Leontien C Kremer; David C Landy; Tracie L Miller; Kevin C Oeffinger; David N Rosenthal; Craig A Sable; Stephen E Sallan; Gautam K Singh; Julia Steinberger; Thomas R Cochran; James D Wilkinson
Journal: Circulation Date: 2013-09-30 Impact factor: 29.690

3. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes.

Authors: Steven E Lipshultz; Tracie L Miller; Rebecca E Scully; Stuart R Lipsitz; Nader Rifai; Lewis B Silverman; Steven D Colan; Donna S Neuberg; Suzanne E Dahlberg; Jacqueline M Henkel; Barbara L Asselin; Uma H Athale; Luis A Clavell; Caroline Laverdière; Bruno Michon; Marshall A Schorin; Stephen E Sallan
Journal: J Clin Oncol Date: 2012-02-27 Impact factor: 44.544

4. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.

Authors: Paul W Burridge; Yong Fuga Li; Elena Matsa; Haodi Wu; Sang-Ging Ong; Arun Sharma; Alexandra Holmström; Alex C Chang; Michael J Coronado; Antje D Ebert; Joshua W Knowles; Melinda L Telli; Ronald M Witteles; Helen M Blau; Daniel Bernstein; Russ B Altman; Joseph C Wu
Journal: Nat Med Date: 2016-04-18 Impact factor: 53.440

Review 5. Doxorubicin targets multiple players: A new view of an old problem.

Authors: Donato Cappetta; Francesca Rossi; Elena Piegari; Federico Quaini; Liberato Berrino; Konrad Urbanek; Antonella De Angelis
Journal: Pharmacol Res Date: 2017-03-20 Impact factor: 7.658

6. The effect of dexrazoxane for clinical and subclinical cardiotoxicity in children with acute myeloid leukemia.

Authors: Jerónimo Sánchez-Medina; Oscar Gonzalez-Ramella; Sergio Gallegos-Castorena
Journal: J Pediatr Hematol Oncol Date: 2010-05 Impact factor: 1.289

7. Left ventricular systolic function assessed by echocardiography in children and adolescents with osteosarcoma treated with doxorubicin alone or in combination with dexrazoxane.

Authors: Ranulfo Pinheiro de Matos Neto; Antônio Sérgio Petrilli; Célia Maria Campos Silva; Orlando Campos Filho; Victor Manuel Oporto; Lourdes de Fátima Gonçalves Gomes; Marcelo Goulart Paiva; Antônio Carlos Camargo Carvalho; Valdir Ambrósio Moisés
Journal: Arq Bras Cardiol Date: 2006-12 Impact factor: 2.000

Letter by Lipshultz Regarding Article, "Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?"

Review 1. The relevance of information generated by in vitro experimental models to clinical doxorubicin cardiotoxicity.

2. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association.

3. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes.

4. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.

Review 5. Doxorubicin targets multiple players: A new view of an old problem.

6. The effect of dexrazoxane for clinical and subclinical cardiotoxicity in children with acute myeloid leukemia.

7. Left ventricular systolic function assessed by echocardiography in children and adolescents with osteosarcoma treated with doxorubicin alone or in combination with dexrazoxane.

Review 8. Chemotherapy-induced cardiotoxicity in children.

9. Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?

10. Cardioprotective effect of early dexrazoxane use in anthracycline treated pediatric patients.

Review 1. Cardiovascular diseases in survivors of childhood cancer.

Review 2. The Role of Mitochondrial Quality Control in Anthracycline-Induced Cardiotoxicity: From Bench to Bedside.

Review 3. Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors.